Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.46 USD
+0.15 (3.48%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.46 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.46 USD
+0.15 (3.48%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.46 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 13.48% and 4.16%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ImmunoGen (IMGN) delivered earnings and revenue surprises of 5.56% and 6.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 0% and 69.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aquestive Therapeutics (AQST) stock based on the movements in the options market lately.
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 7.50% and 10.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 21.43% and 44.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Aquestive Therapeutics (AQST) Q2 Earnings Expected to Decline
by Zacks Equity Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 6.82% and 21.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -30.43% and 11.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Aquestive Therapeutics (AQST) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for January 28th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 2.00% and -3.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aquestive Therapeutics (AQST) stock based on the movements in the options market lately.
Aquestive Therapeutics (AQST) in Focus: Stock Moves 6.4% Higher
by Zacks Equity Research
Aquestive Therapeutics (AQST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 83.72% and 137.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aquestive Therapeutics (AQST) stock based on the movements in the options market lately.
Why Aquestive Therapeutics (AQST) Stock Might be a Great Pick
by Zacks Equity Research
Aquestive Therapeutics (AQST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is Aquestive Therapeutics (AQST) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AQST) Outperforming Other Medical Stocks This Year?
Aquestive Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aquestive Therapeutics.
All You Need to Know About Aquestive Therapeutics (AQST) Rating Upgrade to Buy
by Zacks Equity Research
Aquestive Therapeutics (AQST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will Aquestive Therapeutics (AQST) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aquestive Therapeutics (AQST): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Aquestive Therapeutics (AQST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.